Guglielmi, Valeria
Bellia, Alfonso
Bianchini, Elisa
Medea, Gerardo
Cricelli, Iacopo
Sbraccia, Paolo
Lauro, Davide
Cricelli, Claudio
Lapi, Francesco
Funding for this research was provided by:
Ibsa
Article History
Received: 6 June 2017
Accepted: 28 August 2017
First Online: 14 September 2017
Compliance with ethical standards
:
: Dr. I. Cricelli and Dr. F. Lapi provided consultancies in protocol preparation for epidemiological studies and data analyses for Angelini, Alfa Wassermann, Bayer, and IBSA. Dr. C. Cricelli, and Dr. G. Medea provided clinical consultancies for Angelini, Alfa Wassermann, Bayer, and IBSA. Dr. V. Guglielmi, Dr. A. Bellia, Dr. E. Bianchini, Prof. P. Sbraccia, and Prof. D. Lauro, have no conflict of interest to disclose.
: This is an observational, retrospective, non-interventional study. According to a by-law on the classification and implementation of observational drug-related research, as issued by the Italian National Drug Agency (an entity belonging to the Italian Ministry of Health), the present study does not require approval by an Ethics Committee in Italy (Italian Drug Agency note of 3rd August 2007).